Rounds Report: Crispr Rallied While The FDA Approved Lumivascular – Seeking Alpha
Post Analyst |
Rounds Report: Crispr Rallied While The FDA Approved Lumivascular
Seeking Alpha The bioscience market logged further gains for the second consecutive day this week. Many equities under our coverage continued to move northbound. Crispr Therapeutics topped our list due to its robust rally, one that is powering by the strong … 3 Stocks That Feel Like Netflix in 2002 Is Genome Editing the Next Biotech Breakthrough? An Inside Look at Trading Hot Stocks: Pfizer Inc. (PFE), CRISPR Therapeutics AG (CRSP) |
